Important OptumRx updates to support providers, clinical staff and patients through COVID-19.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 9, 2018 - The FDA approved Icon Bioscience’s Dexycu (dexamethasone intraocular suspension), for the treatment of postoperative inflammation.
Download PDF
Return to publications
